Qiang Md Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Qiang Md Liu has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Bangwei Luo
Second Department of Neurosurgery, First Affiliated Hospital of Kunming Medical University, Kunming, China
1 shared publication - Ben Niu
Second Department of Neurosurgery, First Affiliated Hospital of Kunming Medical University, Kunming, China
1 shared publication Bijiang Md Zhang
Second Department of Neurosurgery, First Affiliated Hospital of Kunming Medical University, Kunming, China
1 shared publicationChen Yuelong
1 shared publication- Dulegeqi Md Man
Department of Neurosurgery, International Mongolia Hospital of Inner Mongolia, Inner Mongolia, China
1 shared publication - Jinghui Li
Second Department of Neurosurgery, First Affiliated Hospital of Kunming Medical University, Kunming 650032, China
1 shared publication
Latest Publications
- Open Access
- 17 July 2026
- Published by IntechOpen
Advances in the Medicinal Potential and Industrialization Prospects of Acid Branch Wood
Acid branch wood is recognized not only as a rare rosewood material esteemed in woodworking and art culture but also for its significant traditional pharmacological heritage and potential medicinal properties. This paper offers an exhaustive examination of the morphological traits, medicinal components, traditional uses, and recent developments in contemporary pharmacological research pertaining to acid branch wood. It provides a comprehensive examination of the mechanisms underlying its therapeutic effects and addresses its potential for commercialization in the healthcare sector, along with the challenges encountered. The research indicates that the prevalence of terpenoids and flavonoids in acid branch wood supports its various pharmacological properties, such as antibacterial, anti-inflammatory, antioxidant, and central nervous system modulatory effects. Its therapeutic applications are primarily achieved through aroma-based therapies, including health-promoting aromatherapy and other non-invasive techniques. Despite preliminary studies demonstrating the scientific significance of acid branch wood, substantial challenges persist, notably the lack of adequate clinical data, obstacles in standardizing the extraction of active compounds, and issues related to sustainable resource management. Anticipated advancements, including improved interdisciplinary collaboration, the development of high value-added functional products, and the formation of a sustainable industrial chain, are projected to realize its distinctive potential in preventive medicine and health management.
- 17 July 2026
- Published by IntechOpen
Open AccessAdvances in the Medicinal Potential and Industrialization Prospects of Acid Branch Wood
Acid branch wood is recognized not only as a rare rosewood material esteemed in woodworking and art culture but also for its significant traditional pharmacological heritage and potential medicinal properties. This paper offers an exhaustive examination of the morphological traits, medicinal components, traditional uses, and recent developments in contemporary pharmacological research pertaining to acid branch wood. It provides a comprehensive examination of the mechanisms underlying its therapeutic effects and addresses its potential for commercialization in the healthcare sector, along with the challenges encountered. The research indicates that the prevalence of terpenoids and flavonoids in acid branch wood supports its various pharmacological properties, such as antibacterial, anti-inflammatory, antioxidant, and central nervous system modulatory effects. Its therapeutic applications are primarily achieved through aroma-based therapies, including health-promoting aromatherapy and other non-invasive techniques. Despite preliminary studies demonstrating the scientific significance of acid branch wood, substantial challenges persist, notably the lack of adequate clinical data, obstacles in standardizing the extraction of active compounds, and issues related to sustainable resource management. Anticipated advancements, including improved interdisciplinary collaboration, the development of high value-added functional products, and the formation of a sustainable industrial chain, are projected to realize its distinctive potential in preventive medicine and health management.
- Open Access
- 24 April 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (17) , e48332
Analysis of core target genes of vagus nerve stimulation in epilepsy, ischemic stroke, and depression: Separate insights from network pharmacology, bioinformatics, and Mendelian randomization
Epilepsy, ischemic stroke, and depression, as common neurological diseases, pose a serious threat to human health. Although vagus nerve stimulation (VNS) has been applied in the treatment of these diseases, its exact mechanism of action remains unclear. This study aims to deeply analyze the relationships between the core target genes of VNS and epilepsy, ischemic stroke, and depression by integrating network pharmacology, bioinformatics, and Mendelian randomization. The results showed that, compared with the control group, 159 differentially expressed genes were identified in the VNS-treated group. These genes were involved in biological processes such as “protein-RNA complex organization” and are enriched in metabolism-related pathways such as the “AMPK signaling pathway.” There were 73, 54, and 108 overlapping genes between VNS-related genes and genes related to epilepsy, ischemic stroke, and depression, respectively. Through network analysis and Mendelian randomization analysis, several core genes that may play a protective role in the corresponding diseases were identified, such as CPT1A , SUCLG1 , IMMT , IVD , and PSMA2 . This study has revealed the potential molecular mechanisms possibly involved in VNS treatment of these neurological diseases. The findings offer crucial clues for further in-depth study of VNS treatment mechanisms, and may boost the development of more precise and effective treatment strategies.
- 24 April 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (17) , e48332
Open AccessAnalysis of core target genes of vagus nerve stimulation in epilepsy, ischemic stroke, and depression: Separate insights from network pharmacology, bioinformatics, and Mendelian randomization
Epilepsy, ischemic stroke, and depression, as common neurological diseases, pose a serious threat to human health. Although vagus nerve stimulation (VNS) has been applied in the treatment of these diseases, its exact mechanism of action remains unclear. This study aims to deeply analyze the relationships between the core target genes of VNS and epilepsy, ischemic stroke, and depression by integrating network pharmacology, bioinformatics, and Mendelian randomization. The results showed that, compared with the control group, 159 differentially expressed genes were identified in the VNS-treated group. These genes were involved in biological processes such as “protein-RNA complex organization” and are enriched in metabolism-related pathways such as the “AMPK signaling pathway.” There were 73, 54, and 108 overlapping genes between VNS-related genes and genes related to epilepsy, ischemic stroke, and depression, respectively. Through network analysis and Mendelian randomization analysis, several core genes that may play a protective role in the corresponding diseases were identified, such as CPT1A , SUCLG1 , IMMT , IVD , and PSMA2 . This study has revealed the potential molecular mechanisms possibly involved in VNS treatment of these neurological diseases. The findings offer crucial clues for further in-depth study of VNS treatment mechanisms, and may boost the development of more precise and effective treatment strategies.